Genes2Me Pvt. Ltd, one of the leading diagnostic laboratories in India, has announced the launch of its Rapi-Q- Point of Care RTPCR solution for 1-8 samples, which is easy to use and gives faster results in less than 45 minutes. Backed by powerful software analysis
In one of the highly complex neurovascular surgeries performed in Karnataka, the surgeons at the HCG Suchirayu Hospitals, Hubli, successfully performed the excision of a Large and complex Arteriovenous Malformation (AVM) on Radha Patil, a 42-year-old female patient. Led by renowned and expert Neurosurgeon Dr.
MyHealthcare has announced the launch of India’s first single screen EMR, a system that allows doctors, clinicians to enter all medical records of a patient encounter on a single screen. The system aims to help doctors experience a more efficient and painless approach to delivering
Indian Stroke Association (ISA) and Quality and Accreditation Institute (QAI) join hands to strengthen Stroke Care across the country through developing specific accreditation standards for Stroke Care. Typically, Accreditation Standards laid down a set of requirements which are usually higher than basic requirements for licensing
Genes2Me announced today the launch of its wide range of Next-generation sequencing (NGS)-based panels for Oncology, Personalized Medicine and Hereditary Diseases. By selectively targeting the clinically significant genes, the NGS panels from Genes2Me enable comprehensive analysis with the most effective sequencing throughput. These panels have
Combines two proven blockbuster monoclonal antibodies: Perjeta® (pertuzumab) and Herceptin® (trastuzumab) in single vial for subcutaneous administration Is also the world’s first subcutaneous therapy for breast cancer that offers faster, more comfortable administration of Perjeta and Herceptin under the skin in just minutes, compared
Assam Cancer Care Foundation, a joint initiative of the Government of Assam and Tata Trusts, set up to address issues like lack of awareness about cancer, poor access to quality medical facilities, and lack of affordability Network of world-class hospitals being set up
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT) — a global leader in healthcare technology, today announced the launch of India’s first
- Becomes world’s first company to bring genomics based infectious diseases diagnostic to hospitals - Universal ID test, a revolutionary single test solution for accurate and timely diagnosis of infectious diseases - Tests to be rolled out over the next three months in partnership with
Patient interactions have crossed the one Million mark, making Pristyn Care a leader in Secondary- care In line with its commitment of enhancing access and ensuring high quality secondary-care surgeries through an innovative care delivery model, Pristyn Care doubled its surgery care centres
